GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corestemchemon Inc (XKRX:166480) » Definitions » Valuation Rank

Corestemchemon (XKRX:166480) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is Corestemchemon Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Corestemchemon Valuation Rank Related Terms

Thank you for viewing the detailed overview of Corestemchemon's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Corestemchemon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corestemchemon Inc (XKRX:166480) » Definitions » Valuation Rank
Comparable Companies
XKRX:378800 XKRX:388870 XKRX:348150 XKRX:383930 XKRX:299660 XKRX:217950 XKRX:049960 XKRX:084990 XKRX:338840 XKRX:235980 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
Pangyo 255 beongil 24 I & C Building, 2nd Floor, yeonggi-do, Bundang-gu, Seongnam, Seoul, KOR, 13486
Website
http://www.corestemchemon.com
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.